Skylands Capital’s Achieve Life Sciences ACHV Stock Holding History

Skylands Capital’s Portfolio ACHV Stock Details ACHV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-27,500	Closed	-$223K	–	144
2020 Q4	$223K	Buy	+27,500	New	+$233K	0.03%	110

Other funds holding ACHV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

PCM

Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Skylands Capital's ACHV Position: Q1 2021 in Review

Skylands Capital sold out of Achieve Life Sciences (ACHV) in Q1 2021, closing a stake of 27,500 shares — an estimated $223K sold.

Skylands Capital first reported a position in ACHV in Q4 2020 and held it in 1 quarter. The position peaked at $223K in Q4 2020. 16 funds tracked by Wall St. Rank hold ACHV as of Q1 2021.

Skylands Capital reported no remaining Achieve Life Sciences position as of Q1 2021 after selling out during the quarter.
Skylands Capital sold 27,500 Achieve Life Sciences shares in Q1 2021, an estimated $223K.
Skylands Capital first reported a position in Achieve Life Sciences in Q4 2020 and held it in 1 quarter.
Skylands Capital's Achieve Life Sciences position peaked at $223K in Q4 2020.
16 funds tracked by Wall St. Rank held Achieve Life Sciences as of Q1 2021.

Based on Skylands Capital's 13F filing for Q1 2021, filed 4 May 2021.